Incentives

All-in cost of a new antibiotic from discovery to 10 years on market

Dear All (and with thanks to Kevin Krause for co-authoring this newsletter), The elements that contribute to the all-in cost of an antibiotic have been reviewed in two prior newsletters: 6 Mar 2020 (focused on cost of R&D to approval): What does an antibiotic cost to develop? What is it worth? How to afford it? 7 Jan

Read More »

UK Pilot Antibiotic Subscription Model: Two candidate antibiotics chosen!

Dear All, Breaking news! Prior newsletters (initial and follow-up) have discussed the UK’s innovative antibiotic subscription pilot (aka, “Netflix for antibiotics”). In brief, the UK intends to identify two innovative antibiotics suitable for being purchased via a delinked model in which the payment to the innovator is a fixed annual fee rather than a per-use

Read More »

US DoD SBIR grants to develop small molecules for MDR Pseudomonas aeruginosa

Dear All, The US Department of Defense (DoD) is offering funds through the Small Business Innovation Research (SBIR) program for a “Novel Antibiotic for the Treatment of Multidrug-Resistant Pseudomonas Aeruginosa Infections.” Antibody, phage, and vaccine approaches are out of scope and the business must be located in the United States. To find the funding offer, navigate

Read More »

AMR Action Fund ($1b for P2-3) seeks Scientific Advisory Board

Dear All, I’ve previously written about the AMR Action Fund (9 Jul 2020 newsletter), a $1b fund created by 20+ global pharma with the intertwined goals of (i) bringing 2-4 new antibacterial antibiotics through Phase 2-3 and approval by 2030 and (ii) creating market conditions that enable sustainable investment in antibiotics. While we know that the

Read More »

Summary of funding initiatives (Simpkin et al.) + E9(R1) Statistical methods update (FDA)

Dear All: Two updates today. First, our colleagues at London School of Economics have just published a review of antibiotic innovation incentives that includes a detailed review of some of the currently available sources of funding (Simpkin VL et al., Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot, 1 Nov 2017). As

Read More »

Incentives for antibiotics: Recent papers, with an emphasis on Pull

Dear All:  For your weekend reading list, I have some papers on the topic of (mostly pull) incentives for antibiotics. First, I previously wrote about the survey from TATFAR (Transatlantic Task Force on Antimicrobial Resistance) of 6 possible pull models (higher reimbursement, diagnostic confirmation, market entry rewards both fully and partially delinked, tradable exclusivity vouchers, and an options market).

Read More »

CDC funds more than 20 AMR-focused projects!

​Dear All:  CDC has today announced $9m in funding for more than 20 new projects focused on slowing or combating antimicrobial resistance. Part of the CDC’s Antibiotic Resistance Solutions Initiative, these projects span a broad range that includes surveillance (C. auris, antibiotic resistance in a watershed, antibiotic resistance in poultry farms), diagnostics (POC tools, what’s in hospital sewage

Read More »
Scroll to Top